{"id":"https://openalex.org/W4385788674","doi":"https://doi.org/10.1016/j.ejpb.2023.08.008","title":"Compliance and regulatory considerations for the implementation of the multi-attribute-method by mass spectrometry in a quality control laboratory","display_name":"Compliance and regulatory considerations for the implementation of the multi-attribute-method by mass spectrometry in a quality control laboratory","alternate_titles":[],"publication_year":2023,"publication_date":"2023-08-13","ids":{"openalex":"https://openalex.org/W4385788674","doi":"https://doi.org/10.1016/j.ejpb.2023.08.008","pmid":"https://pubmed.ncbi.nlm.nih.gov/37582411"},"language":"en","primary_location":{"id":"doi:10.1016/j.ejpb.2023.08.008","doi":"https://doi.org/10.1016/j.ejpb.2023.08.008","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ejpb.2023.08.008","pdf_url":null,"source":{"id":"https://openalex.org/S122302516","display_name":"European Journal of Pharmaceutics and Biopharmaceutics","issn_l":"0939-6411","issn":["0939-6411","1873-3441"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Pharmaceutics and Biopharmaceutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4385788674"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1016/j.ejpb.2023.08.008","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5018935998","display_name":"Annick Gervais","orcid":"https://orcid.org/0009-0001-9555-0624","observed_orcids":["https://orcid.org/0009-0001-9555-0624"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Annick Gervais","raw_affiliation_strings":["Analytical Development Sciences for Biologicals, UCB, Chemin du Foriest, 1420 Braine L'Alleud, Belgium. Electronic address: annick.gervais@ucb.com","Analytical Development Sciences for Biologicals, UCB, Chemin du Foriest, 1420 Braine L'Alleud, Belgium"],"raw_orcid":"https://orcid.org/0009-0001-9555-0624","affiliations":[{"raw_affiliation_string":"Analytical Development Sciences for Biologicals, UCB, Chemin du Foriest, 1420 Braine L'Alleud, Belgium. Electronic address: annick.gervais@ucb.com","institution_ids":[]},{"raw_affiliation_string":"Analytical Development Sciences for Biologicals, UCB, Chemin du Foriest, 1420 Braine L'Alleud, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079311346","display_name":"Eef H.C. Dirksen","orcid":"https://orcid.org/0000-0002-5246-8604","observed_orcids":["https://orcid.org/0000-0002-5246-8604"]},"institutions":[{"id":"https://openalex.org/I4405267618","display_name":"Byondis BV (Netherlands)","ror":"https://ror.org/03kxd1c72","country_code":"NL","type":"company","lineage":["https://openalex.org/I4405267618"]}],"countries":["NL"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Eef H.C. Dirksen","raw_affiliation_strings":["Analytical Development and Quality Control, Byondis, Microweg 22, 6545 CM, Nijmegen, the Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Analytical Development and Quality Control, Byondis, Microweg 22, 6545 CM, Nijmegen, the Netherlands","institution_ids":["https://openalex.org/I4405267618"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103011286","display_name":"Thomas Pohl","orcid":"https://orcid.org/0009-0002-7454-8186","observed_orcids":["https://orcid.org/0009-0002-7454-8186"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Thomas Pohl","raw_affiliation_strings":["Biologics Analytical Development, Novartis Pharma AG, Klybeckstrasse 141, CH-4057 Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biologics Analytical Development, Novartis Pharma AG, Klybeckstrasse 141, CH-4057 Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032123836","display_name":"Karoline Bechtold-Peters","orcid":"https://orcid.org/0000-0001-7451-3819","observed_orcids":["https://orcid.org/0000-0001-7451-3819"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Karoline Bechtold-Peters","raw_affiliation_strings":["Biologics Drug Product Development, Novartis Pharma AG, Klybeckstrasse 141, CH-4057 Basel, Switzerland"],"raw_orcid":"https://orcid.org/0000-0001-7451-3819","affiliations":[{"raw_affiliation_string":"Biologics Drug Product Development, Novartis Pharma AG, Klybeckstrasse 141, CH-4057 Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065631816","display_name":"Will Burkitt","orcid":"https://orcid.org/0000-0002-3778-0448","observed_orcids":["https://orcid.org/0000-0002-3778-0448"]},"institutions":[{"id":"https://openalex.org/I4210134054","display_name":"UCB Pharma (United Kingdom)","ror":"https://ror.org/03428qp74","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210134054","https://openalex.org/I85722119"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Will Burkitt","raw_affiliation_strings":["Biological Characterisation Product Development Sciences, UCB, 216 Bath Road, Slough, SL1 3WE, UK"],"raw_orcid":"https://orcid.org/0000-0002-3778-0448","affiliations":[{"raw_affiliation_string":"Biological Characterisation Product Development Sciences, UCB, 216 Bath Road, Slough, SL1 3WE, UK","institution_ids":["https://openalex.org/I4210134054"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031905242","display_name":"Valerio D\u2019Alessio","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I862255436","display_name":"Merck Serono S.p.A. (Italy)","ror":"https://ror.org/01z6wpz16","country_code":"IT","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I862255436"]}],"countries":["IT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Valerio D'Alessio","raw_affiliation_strings":["Analytical Development & Innovation NBE, Merck Serono S.p.A, Via Luigi Einaudi, 11, 00012 Guidonia Montecelio - Rome, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Analytical Development & Innovation NBE, Merck Serono S.p.A, Via Luigi Einaudi, 11, 00012 Guidonia Montecelio - Rome, Italy","institution_ids":["https://openalex.org/I862255436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026172424","display_name":"Simone Greven","orcid":"https://orcid.org/0009-0004-4717-8938","observed_orcids":["https://orcid.org/0009-0004-4717-8938"]},"institutions":[{"id":"https://openalex.org/I67348948","display_name":"Bayer (Germany)","ror":"https://ror.org/04hmn8g73","country_code":"DE","type":"company","lineage":["https://openalex.org/I67348948"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Simone Greven","raw_affiliation_strings":["Pharmaceuticals, Biological Development, Bayer AG, Friedrich-Ebert-Strasse 217-333, 42117 Wuppertal, Germany"],"raw_orcid":"https://orcid.org/0009-0004-4717-8938","affiliations":[{"raw_affiliation_string":"Pharmaceuticals, Biological Development, Bayer AG, Friedrich-Ebert-Strasse 217-333, 42117 Wuppertal, Germany","institution_ids":["https://openalex.org/I67348948"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065650740","display_name":"Andrew Lennard","orcid":"https://orcid.org/0000-0002-9525-4112","observed_orcids":["https://orcid.org/0000-0002-9525-4112"]},"institutions":[{"id":"https://openalex.org/I4210117596","display_name":"Amgen (United Kingdom)","ror":"https://ror.org/02gvvc992","country_code":"GB","type":"company","lineage":["https://openalex.org/I1320553840","https://openalex.org/I4210117596"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Andrew Lennard","raw_affiliation_strings":["Amgen Ltd, 4 Uxbridge Business Park, Sanderson Road, Uxbridge, UB8 1DH, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Ltd, 4 Uxbridge Business Park, Sanderson Road, Uxbridge, UB8 1DH, UK","institution_ids":["https://openalex.org/I4210117596"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100372247","display_name":"Xue Li","orcid":"https://orcid.org/0000-0002-9850-5132","observed_orcids":["https://orcid.org/0000-0002-9850-5132"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Xue Li","raw_affiliation_strings":["Biologics Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, NJ 08901, USA","Biologics Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, USA"],"raw_orcid":"https://orcid.org/0000-0002-9850-5132","affiliations":[{"raw_affiliation_string":"Biologics Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, NJ 08901, USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Biologics Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054303139","display_name":"Christopher L\u00f6\u00dfner","orcid":"https://orcid.org/0000-0003-1261-0335","observed_orcids":["https://orcid.org/0000-0003-1261-0335"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Christopher L\u00f6ssner","raw_affiliation_strings":["Analytical Dev. Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Stra\u00dfe 65, 88397 Biberach an der Ri\u00df, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Analytical Dev. Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Stra\u00dfe 65, 88397 Biberach an der Ri\u00df, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080608355","display_name":"Ben Niu","orcid":"https://orcid.org/0000-0002-6646-9085","observed_orcids":["https://orcid.org/0000-0002-6646-9085"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ben Niu","raw_affiliation_strings":["Biotherapeutics, Bristol Myers Squibb, 4224 Campus Point Court, San Diego, CA 92121, USA","Biotherapeutics, Bristol Myers Squibb, 4224 Campus Point Court, San Diego, California 92121, USA"],"raw_orcid":"https://orcid.org/0000-0002-6646-9085","affiliations":[{"raw_affiliation_string":"Biotherapeutics, Bristol Myers Squibb, 4224 Campus Point Court, San Diego, CA 92121, USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Biotherapeutics, Bristol Myers Squibb, 4224 Campus Point Court, San Diego, California 92121, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108133064","display_name":"Dietmar Reusch","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Dietmar Reusch","raw_affiliation_strings":["Pharma Technical Development, Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharma Technical Development, Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046169488","display_name":"Tom\u00e1s O\u2019Riordan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095997","display_name":"Eli Lilly (Ireland)","ror":"https://ror.org/00pvn1h36","country_code":"IE","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210095997"]}],"countries":["IE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Tom\u00e1s O'Riordan","raw_affiliation_strings":["Eli Lilly Kinsale Limited, Dunderrow, Kinsale, Co. Cork, P17NY71, Ireland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly Kinsale Limited, Dunderrow, Kinsale, Co. Cork, P17NY71, Ireland","institution_ids":["https://openalex.org/I4210095997"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032040549","display_name":"Justin W. Shearer","orcid":"https://orcid.org/0000-0003-0331-2301","observed_orcids":["https://orcid.org/0000-0003-0331-2301"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Justin W. Shearer","raw_affiliation_strings":["Analytical Development, GSK, 709 Swedeland Road, King of Prussia, PA 19406, USA","Analytical Development, GSK, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, USA"],"raw_orcid":"https://orcid.org/0000-0003-0331-2301","affiliations":[{"raw_affiliation_string":"Analytical Development, GSK, 709 Swedeland Road, King of Prussia, PA 19406, USA","institution_ids":["https://openalex.org/I4210114143"]},{"raw_affiliation_string":"Analytical Development, GSK, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, USA","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":null,"display_name":"David Spencer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"David Spencer","raw_affiliation_strings":["BioPharmaceutical Development, Ipsen Biopharm Limited, 9 Ash Road, Wrexham Industrial Estate, Wrexham, LL13 9UF, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BioPharmaceutical Development, Ipsen Biopharm Limited, 9 Ash Road, Wrexham Industrial Estate, Wrexham, LL13 9UF, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002578606","display_name":"Wei Xu","orcid":"https://orcid.org/0000-0003-3460-0330","observed_orcids":["https://orcid.org/0000-0003-3460-0330"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Wei Xu","raw_affiliation_strings":["Analytical Sciences, BioPharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD 20878, USA","Analytical Sciences, BioPharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, Maryland 20878, USA"],"raw_orcid":"https://orcid.org/0000-0003-3460-0330","affiliations":[{"raw_affiliation_string":"Analytical Sciences, BioPharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD 20878, USA","institution_ids":["https://openalex.org/I4210150756"]},{"raw_affiliation_string":"Analytical Sciences, BioPharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, Maryland 20878, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5068254672","display_name":"Linda Yi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Linda Yi","raw_affiliation_strings":["Analytical Development, Biogen, 5000 Davis Drive, Research Triangle Park, NC 27709, USA","Analytical Development, Biogen, 5000 Davis Drive, Research Triangle Park, North Carolina 27709, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Analytical Development, Biogen, 5000 Davis Drive, Research Triangle Park, NC 27709, USA","institution_ids":["https://openalex.org/I1297540436"]},{"raw_affiliation_string":"Analytical Development, Biogen, 5000 Davis Drive, Research Triangle Park, North Carolina 27709, USA","institution_ids":["https://openalex.org/I1297540436"]}]}],"institutions":[],"countries_distinct_count":7,"institutions_distinct_count":12,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4270,"currency":"USD","value_usd":4270},"apc_paid":{"value":4270,"currency":"USD","value_usd":4270},"fwci":2.3612,"has_fulltext":false,"cited_by_count":26,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.89366638,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":95,"max":100},"biblio":{"volume":"191","issue":null,"first_page":"57","last_page":"67"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.8393999934196472,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.8393999934196472,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11124","display_name":"Protein purification and stability","score":0.1145000010728836,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11460","display_name":"Analytical Methods in Pharmaceuticals","score":0.024399999529123306,"subfield":{"id":"https://openalex.org/subfields/1602","display_name":"Analytical Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multi-attribute-method","display_name":"multi-attribute method","score":0.9559999704360962},{"id":"https://openalex.org/keywords/peptide-mapping","display_name":"peptide mapping","score":0.8159999847412109},{"id":"https://openalex.org/keywords/liquid-chromatography-mass-spectrometry","display_name":"liquid chromatography-mass spectrometry","score":0.8349999785423279},{"id":"https://openalex.org/keywords/batch-release","display_name":"batch release","score":0.5690000057220459},{"id":"https://openalex.org/keywords/stability-testing","display_name":"stability testing","score":0.9350000023841858},{"id":"https://openalex.org/keywords/regulatory-aspects","display_name":"regulatory considerations","score":0.847000002861023},{"id":"https://openalex.org/keywords/biopharmaceutical-quality-control","display_name":"biopharmaceutical quality control","score":0.8870000243186951},{"id":"https://openalex.org/keywords/product-characterization","display_name":"product characterization","score":0.5619999766349792},{"id":"https://openalex.org/keywords/process-characterization","display_name":"process characterization","score":0.7329999804496765}],"concepts":[{"id":"https://openalex.org/C2779709869","wikidata":"https://www.wikidata.org/wiki/Q1292017","display_name":"Good manufacturing practice","level":3,"score":0.7319673895835876},{"id":"https://openalex.org/C2779530757","wikidata":"https://www.wikidata.org/wiki/Q1207505","display_name":"Quality (philosophy)","level":2,"score":0.6647433042526245},{"id":"https://openalex.org/C2781047461","wikidata":"https://www.wikidata.org/wiki/Q679692","display_name":"Biopharmaceutical","level":2,"score":0.6570595502853394},{"id":"https://openalex.org/C2775924081","wikidata":"https://www.wikidata.org/wiki/Q55608371","display_name":"Control (management)","level":2,"score":0.5408987402915955},{"id":"https://openalex.org/C2781050149","wikidata":"https://www.wikidata.org/wiki/Q552070","display_name":"Good laboratory practice","level":4,"score":0.529600977897644},{"id":"https://openalex.org/C90673727","wikidata":"https://www.wikidata.org/wiki/Q901718","display_name":"Product (mathematics)","level":2,"score":0.5177758932113647},{"id":"https://openalex.org/C2779652045","wikidata":"https://www.wikidata.org/wiki/Q507443","display_name":"Pharmaceutical industry","level":2,"score":0.5094946026802063},{"id":"https://openalex.org/C98045186","wikidata":"https://www.wikidata.org/wiki/Q205663","display_name":"Process (computing)","level":2,"score":0.507075309753418},{"id":"https://openalex.org/C2781460075","wikidata":"https://www.wikidata.org/wiki/Q1399332","display_name":"Compliance (psychology)","level":2,"score":0.4728781580924988},{"id":"https://openalex.org/C195094911","wikidata":"https://www.wikidata.org/wiki/Q14167904","display_name":"Process management","level":1,"score":0.4411516785621643},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.42887404561042786},{"id":"https://openalex.org/C162356407","wikidata":"https://www.wikidata.org/wiki/Q180809","display_name":"Mass spectrometry","level":2,"score":0.4211149215698242},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.39778488874435425},{"id":"https://openalex.org/C183696295","wikidata":"https://www.wikidata.org/wiki/Q2487696","display_name":"Biochemical engineering","level":1,"score":0.3968826234340668},{"id":"https://openalex.org/C106436119","wikidata":"https://www.wikidata.org/wiki/Q836575","display_name":"Quality assurance","level":3,"score":0.3449285626411438},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.34018245339393616},{"id":"https://openalex.org/C21547014","wikidata":"https://www.wikidata.org/wiki/Q1423657","display_name":"Operations management","level":1,"score":0.27910012006759644},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.26176267862319946},{"id":"https://openalex.org/C127413603","wikidata":"https://www.wikidata.org/wiki/Q11023","display_name":"Engineering","level":0,"score":0.2609691619873047},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.23633337020874023},{"id":"https://openalex.org/C43617362","wikidata":"https://www.wikidata.org/wiki/Q170050","display_name":"Chromatography","level":1,"score":0.1993340253829956},{"id":"https://openalex.org/C2780511413","wikidata":"https://www.wikidata.org/wiki/Q18749628","display_name":"Regulatory affairs","level":2,"score":0.17214643955230713},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.1675049364566803},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.09985169768333435},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.09557449817657471},{"id":"https://openalex.org/C138885662","wikidata":"https://www.wikidata.org/wiki/Q5891","display_name":"Philosophy","level":0,"score":0.0},{"id":"https://openalex.org/C154945302","wikidata":"https://www.wikidata.org/wiki/Q11660","display_name":"Artificial intelligence","level":1,"score":0.0},{"id":"https://openalex.org/C77805123","wikidata":"https://www.wikidata.org/wiki/Q161272","display_name":"Social psychology","level":1,"score":0.0},{"id":"https://openalex.org/C111472728","wikidata":"https://www.wikidata.org/wiki/Q9471","display_name":"Epistemology","level":1,"score":0.0},{"id":"https://openalex.org/C2524010","wikidata":"https://www.wikidata.org/wiki/Q8087","display_name":"Geometry","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C111919701","wikidata":"https://www.wikidata.org/wiki/Q9135","display_name":"Operating system","level":1,"score":0.0},{"id":"https://openalex.org/C2778618615","wikidata":"https://www.wikidata.org/wiki/Q4008393","display_name":"External quality assessment","level":2,"score":0.0},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D002853","descriptor_name":"Chromatography, Liquid","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D004345","descriptor_name":"Drug Industry","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D007753","descriptor_name":"Laboratories","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D011786","descriptor_name":"Quality Control","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013058","descriptor_name":"Mass Spectrometry","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1016/j.ejpb.2023.08.008","doi":"https://doi.org/10.1016/j.ejpb.2023.08.008","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ejpb.2023.08.008","pdf_url":null,"source":{"id":"https://openalex.org/S122302516","display_name":"European Journal of Pharmaceutics and Biopharmaceutics","issn_l":"0939-6411","issn":["0939-6411","1873-3441"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Pharmaceutics and Biopharmaceutics","raw_type":"journal-article"},{"id":"doi:10.2139/ssrn.4510607","doi":"https://doi.org/10.2139/ssrn.4510607","is_oa":true,"landing_page_url":"https://doi.org/10.2139/ssrn.4510607","pdf_url":null,"source":{"id":"https://openalex.org/S4210172589","display_name":"SSRN Electronic Journal","issn_l":"1556-5068","issn":["1556-5068"],"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1318003438","host_organization_name":"RELX Group (Netherlands)","host_organization_lineage":["https://openalex.org/I1318003438"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"posted-content"},{"id":"pmid:37582411","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/37582411","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V","raw_type":"Journal Article"},{"id":"pmh:oai:oak.novartis.com:50837","doi":null,"is_oa":false,"landing_page_url":"https://oak.novartis.com/50837/","pdf_url":null,"source":{"id":"https://openalex.org/S4306400709","display_name":"The Novartis Repository (Novartis)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1283582996","host_organization_name":"Novartis (Switzerland)","host_organization_lineage":["https://openalex.org/I1283582996"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Article"}],"best_oa_location":{"id":"doi:10.1016/j.ejpb.2023.08.008","doi":"https://doi.org/10.1016/j.ejpb.2023.08.008","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ejpb.2023.08.008","pdf_url":null,"source":{"id":"https://openalex.org/S122302516","display_name":"European Journal of Pharmaceutics and Biopharmaceutics","issn_l":"0939-6411","issn":["0939-6411","1873-3441"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Pharmaceutics and Biopharmaceutics","raw_type":"journal-article"},"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":28,"referenced_works":["https://openalex.org/W1865824976","https://openalex.org/W1980086200","https://openalex.org/W1999481657","https://openalex.org/W2028884049","https://openalex.org/W2774281697","https://openalex.org/W2981266307","https://openalex.org/W2997824902","https://openalex.org/W3027729032","https://openalex.org/W3044195134","https://openalex.org/W3046973649","https://openalex.org/W3119965917","https://openalex.org/W3131380995","https://openalex.org/W3134562340","https://openalex.org/W3173704908","https://openalex.org/W3194008781","https://openalex.org/W4206950120","https://openalex.org/W4285499371","https://openalex.org/W4293162417","https://openalex.org/W4307039467","https://openalex.org/W4308313294","https://openalex.org/W4308797684","https://openalex.org/W4310364218","https://openalex.org/W4318263205","https://openalex.org/W4321435614","https://openalex.org/W4353072653","https://openalex.org/W4365483718","https://openalex.org/W4367845836","https://openalex.org/W4383218737"],"related_works":["https://openalex.org/W4367845836","https://openalex.org/W4365483718","https://openalex.org/W7215091242","https://openalex.org/W7044146901","https://openalex.org/W4385230806","https://openalex.org/W7212232433","https://openalex.org/W2981266307","https://openalex.org/W7222963009","https://openalex.org/W4210296462","https://openalex.org/W7203642029"],"abstract_inverted_index":{"Multi-attribute":[0],"methods":[1],"employing":[2],"mass":[3,87],"spectrometry":[4,88],"are":[5,18],"applied":[6],"throughout":[7],"the":[8,33,48,65,79,134,137],"biopharmaceutical":[9],"industry":[10,124],"for":[11,26,76],"product":[12],"and":[13,29,43,51,112,143],"process":[14],"characterization":[15],"purposes":[16],"but":[17],"not":[19],"yet":[20],"widely":[21],"accepted":[22],"as":[23],"a":[24,69,91,121],"method":[25,81],"batch":[27],"release":[28],"stability":[30],"testing":[31],"under":[32,133],"good":[34],"manufacturing":[35],"practice":[36],"(GMP)":[37],"regime,":[38],"due":[39],"to":[40,109],"limited":[41],"experience":[42],"level":[44],"of":[45,54,68,78,123,136,140],"comfort":[46],"with":[47],"technical,":[49],"compliance":[50,111],"regulatory":[52,113],"aspects":[53],"its":[55],"implementation":[56,77],"at":[57,73],"quality":[58],"control":[59],"(QC)":[60],"laboratories.":[61],"This":[62,115],"article":[63],"is":[64],"second":[66,104],"part":[67,96,105],"two-tiered":[70],"publication":[71,116],"aiming":[72],"providing":[74],"guidance":[75],"multi-attribute":[80],"by":[82,120],"peptide":[83],"mapping":[84],"liquid":[85],"chromatography":[86],"(MAM)":[89],"in":[90],"QC":[92],"laboratory.":[93],"The":[94],"first":[95],"[1]":[97],"focuses":[98],"on":[99],"technical":[100],"considerations,":[101],"while":[102],"this":[103],"provides":[106],"considerations":[107],"related":[108],"GMP":[110],"aspects.":[114],"has":[117],"been":[118],"prepared":[119],"group":[122],"experts":[125],"representing":[126],"14":[127],"globally":[128],"acting":[129],"major":[130],"biotechnology":[131],"companies":[132],"umbrella":[135],"European":[138],"Federation":[139],"Pharmaceutical":[141],"Industries":[142],"Associations":[144],"(EFPIA)":[145],"Manufacturing":[146],"&":[147],"Quality":[148],"Expert":[149],"Group":[150],"(MQEG).":[151]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4385788674","counts_by_year":[{"year":2026,"cited_by_count":13},{"year":2025,"cited_by_count":10},{"year":2024,"cited_by_count":3}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2023-08-13T00:00:00"}
